3′-deoxy nucleosides for the treatment of HCV
US9309275B2 · kind B2 · utility
17Cited by
150References
24Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 3, 2014 |
| Grant date | Apr 12, 2016 |
| Priority date | — |
| Expiry date | Mar 3, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3′-deoxy nucleoside compounds according to Formula 3001a or 3001b:or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base1 and Base2 are as provided herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.